Mendelian randomization of blood lipids for coronary heart disease

Michael V. Holmes(University of Pennsylvania), Folkert W. Asselbergs(University College London), Tom Palmer(University of Warwick), Fotios Drenos(University of Bristol), Matthew B. Lanktree(McMaster University), Christopher P. Nelson(University of Leicester), Caroline Dale(University of London), Sandosh Padmanabhan(University of Glasgow), Chris Finan(University College London), Daniel I. Swerdlow(University College London), Vinicius Tragante(University Medical Center Utrecht), Erik P.A. van Iperen(Academic Medical Center), Suthesh Sivapalaratnam(Academic Medical Center), Sonia Shah(University College London), Clara C. Elbers(Children's Hospital of Philadelphia), Tina Shah(University College London), Jorgen Engmann(University College London), Claudia Giambartolomei(University College London), Jon White(University College London), Delilah Zabaneh(University College London), Reecha Sofat(University College London), Stela McLachlan(University of Edinburgh), Pieter A. Doevendans(University Medical Center Utrecht), Anthony J. Balmforth(University of Leeds), Alistair S. Hall(University of Leeds), Kari E. North(University of North Carolina at Chapel Hill), Berta Almoguera(Children's Hospital of Philadelphia), Ron C. Hoogeveen(Baylor College of Medicine), Mary Cushman(University of Vermont), Myriam Fornage(The University of Texas Health Science Center at Houston), Sanjay R. Patel(Brigham and Women's Hospital), Susan Redline(Brigham and Women's Hospital), David S. Siscovick(University of Washington), Michael Y. Tsai(University of Minnesota), Konrad J. Karczewski(Stanford University), Marten H. Hofker(University Medical Center Groningen), W. M. Monique Verschuren(National Institute for Public Health and the Environment), Michiel L. Bots(University Medical Center Utrecht), Yvonne T. van der Schouw(University Medical Center Utrecht), Olle Melander(Lund University), Anna F. Dominiczak(University of Glasgow), Richard Morris(University College London), Yoav Ben‐Shlomo(University of Bristol), Jackie F. Price(University of Edinburgh), Meena Kumari(University College London), Jens Baumert(Helmholtz Zentrum München), Annette Peters(Helmholtz Zentrum München), Barbara Thorand(Helmholtz Zentrum München), Wolfgang Köenig(Universität Ulm), Tom R. Gaunt(University of Bristol), Steve E. Humphries(University College London), Robert Clarke(University of Oxford), Hugh Watkins(University of Oxford), Martin Farrall(University of Oxford), James G. Wilson(Jackson Memorial Hospital), Stephen S. Rich(University of Virginia), Paul I. W. de Bakker(University Medical Center Utrecht), Leslie A. Lange(University of North Carolina at Chapel Hill), George Davey Smith(University of Bristol), Alex P. Reiner(Fred Hutch Cancer Center), Philippa J. Talmud(University College London), Mika Kivimäki(University College London), Debbie A. Lawlor(University of Bristol), Frank Dudbridge(London School of Hygiene & Tropical Medicine), Nilesh J. Samani(University of Leicester), Brendan J. Keating(Children's Hospital of Philadelphia), Aroon D. Hingorani(University College London), Juan P. Casas(University College London)
European Heart Journal
January 28, 2014
Cited by 790Open Access
Full Text

Abstract

AIMS: To investigate the causal role of high-density lipoprotein cholesterol (HDL-C) and triglycerides in coronary heart disease (CHD) using multiple instrumental variables for Mendelian randomization. METHODS AND RESULTS: We developed weighted allele scores based on single nucleotide polymorphisms (SNPs) with established associations with HDL-C, triglycerides, and low-density lipoprotein cholesterol (LDL-C). For each trait, we constructed two scores. The first was unrestricted, including all independent SNPs associated with the lipid trait identified from a prior meta-analysis (threshold P < 2 × 10(-6)); and the second a restricted score, filtered to remove any SNPs also associated with either of the other two lipid traits at P ≤ 0.01. Mendelian randomization meta-analyses were conducted in 17 studies including 62,199 participants and 12,099 CHD events. Both the unrestricted and restricted allele scores for LDL-C (42 and 19 SNPs, respectively) associated with CHD. For HDL-C, the unrestricted allele score (48 SNPs) was associated with CHD (OR: 0.53; 95% CI: 0.40, 0.70), per 1 mmol/L higher HDL-C, but neither the restricted allele score (19 SNPs; OR: 0.91; 95% CI: 0.42, 1.98) nor the unrestricted HDL-C allele score adjusted for triglycerides, LDL-C, or statin use (OR: 0.81; 95% CI: 0.44, 1.46) showed a robust association. For triglycerides, the unrestricted allele score (67 SNPs) and the restricted allele score (27 SNPs) were both associated with CHD (OR: 1.62; 95% CI: 1.24, 2.11 and 1.61; 95% CI: 1.00, 2.59, respectively) per 1-log unit increment. However, the unrestricted triglyceride score adjusted for HDL-C, LDL-C, and statin use gave an OR for CHD of 1.01 (95% CI: 0.59, 1.75). CONCLUSION: The genetic findings support a causal effect of triglycerides on CHD risk, but a causal role for HDL-C, though possible, remains less certain.


Related Papers

No related papers found

Powered by citation graph analysis